Consumer medicine information

MZ Clonidine HCl injection

Clonidine hydrochloride

BRAND INFORMATION

Brand name

MZ Clonidine HCl Injection

Active ingredient

Clonidine hydrochloride

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using MZ Clonidine HCl injection.

What is in this leaflet

This leaflet answers some common questions about MZ Clonidine HCl Injection.

It does not contain all the available information

It does not take the place of talking to your doctor or pharmacist.

All medicines have benefits and risks. Your doctor has weighed the risks of you using the MZ Clonidine HCl Injection against the benefits they expect it will have for you.

If you have any concerns about being treated with MZ Clonidine HCl Injection, ask your doctor or pharmacist.

This leaflet was last updated on the date at the end of this leaflet. More recent information may be available. The latest Consumer Medicine Information is available from your pharmacist, doctor, or from www.tga.gov.au and may contain important information about the medicine and its use of which you should be aware.

Keep this leaflet. You may need to read it again.

What MZ Clonidine HCl Injection is used for

MZ Clonidine HCl Injection lowers high blood pressure, also called hypertension.

Everyone has blood pressure. This pressure helps your blood move around your body. Your blood pressure may be different at different times of the day. You have hypertension when your blood pressure stays higher than normal, even when you are calm or relaxed.

There are usually no signs of hypertension. The only way of knowing that you have hypertension is to have your blood pressure checked on a regular basis. You may feel fine and have no symptoms, but if high blood pressure is not treated, it can lead to serious health problems (such as heart disease).

How MZ Clonidine HCl Injection works

MZ Clonidine HCl Injection works by relaxing and widening blood vessels and so helps to lower your blood pressure.

Ask your doctor if you have any questions about why this medicine is being given to you. Your doctor may have prescribed it for another reason.

Before you use MZ Clonidine HCl Injection

When you should not be given it

You should not be given MZ Clonidine HCl Injection if you have an allergy to:

  • any medicine containing clonidine
  • any of the ingredients listed at the end of this leaflet.

Some of the symptoms of an allergic reaction may include:

  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin.

MZ Clonidine HCl Injection should not be given to you if you have certain heart problems, such as irregular/slow heartbeat.

You should not be given this medicine if you are pregnant. It may affect your developing baby if you are given it during pregnancy.

Do not breast-feed if you are given this medicine. The active ingredient in MZ Clonidine HCl Injection passes into breast milk and there is a possibility that your baby may be affected.

This medicine should not be given to a child under the age of 18 years of age.

Serious side effects have been observed when clonidine, the active ingredient in MZ Clonidine HCl Injection is used with methylphenidate in children with ADHD. Therefore, MZ Clonidine HCl Injection in this combination is not recommended.

MZ Clonidine HCl Injection must not be used after the expiry date printed on the pack or ampoule or if the packaging is torn or shows signs of tampering.

If you are not sure whether you should be given this medicine, talk to your doctor.

Before you start to use it:

Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.

Tell your doctor if you have or have had any of the following medical conditions:

  • heart failure or any heart or circulation problem
  • stroke, or transient ischaemic attack (TIA)
  • mental depression
  • sugar diabetes
  • nerve damage, which may lead to weakness in the arms and legs
  • constipation
  • phaeochromocytoma (a rare tumour of the adrenal gland)
  • any problems with your kidneys.

If you are uncertain as to whether you have, or have had, any of these conditions you should raise those concerns with your doctor.

If you have not told your doctor about any of the above, tell him/her before you are given MZ Clonidine HCl Injection.

Taking other medicines

Tell your doctor if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and MZ Clonidine HCl Injection may interfere with each other. These include:

  • other medicines for high blood pressure
  • medicines for heart problems
  • alcohol
  • medicines used to control mood swings and some types of depression
  • medicines used to relieve pain, swelling or other symptoms of inflammation.

These medicines may be affected by MZ Clonidine HCl Injection or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.

Your doctor and pharmacist have more information on medicines to be careful with or avoid while being given this medicine.

Taking MZ Clonidine HCl Injection

How it is given

MZ Clonidine HCl Injection can be given as an injection into a muscle or as a slow injection into a vein (over five minutes).

MZ Clonidine HCl Injection should only be given to patients in a lying position.

MZ Clonidine HCl Injection should only be used under the supervision of a doctor and in a setting where appropriate equipment is readily available for diagnosis and patient monitoring.

If you take too much (overdose)

As MZ Clonidine HCl Injection is given to you under the supervision of your doctor, it is very unlikely that you will receive too much.

Symptoms of an overdose may include slow heartbeat, drowsiness, temporarily stopping breathing and coma. Other signs include dizziness, weakness, lethargy, feeling cold, vomiting, looking pale, or having an irregular heartbeat.

Tell your doctor or nurse immediately if you experience any signs of overdose, or, if you are not in hospital, or contact the Australian Poisons information Centre on 13 11 26 (AUS), or go to the Emergency department at your nearest hospital. You may need urgent medical attention.

While you are being given MZ Clonidine HCl Injection

Things you must do:

Tell any other doctors, dentists, and pharmacists who treat you that you have been given this medicine.

Side effects

Tell your doctor or nurse as soon as possible if you do not feel well while you are being given MZ Clonidine HCl Injection.

All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects.

Do not be alarmed by the following lists of side effects. You may not experience any of them.

Ask your doctor or nurse to answer any questions you may have.

The more frequently reported side effects of MZ Clonidine HCl Injection are light-headedness when you stand up suddenly, drowsiness, dryness of the mouth, nausea and vomiting.

Less frequently reported side effects of MZ Clonidine HCl Injection include the following:

  • blurred vision
  • dizziness
  • confusion
  • headache
  • sleep disturbances
  • mental depression
  • irrational or abnormal thoughts
  • irritability
  • decreased sexual drive / impotence
  • generally feeling unwell
  • thinning of hair
  • rash / hives / itching
  • constipation
  • dryness of the nose and eyes
  • pain in the salivary glands
  • tingling or numbness of the hands or feet
  • larger breasts than normal, in men
  • slow or irregular heart beat
  • blood glucose increased.

Occasional reports of abnormal liver function tests and cases of hepatitis have also been reported.

Tell your doctor or nurse as soon as possible if you experience any side effects during or after treatment with MZ Clonidine HCl Injection, so that these may be properly treated.

Other side effects not listed above may also occur in some people.

Tell your doctor or nurse if you notice anything unusual, during or after treatment with MZ Clonidine HCl Injection.

After being given MZ Clonidine HCl Injection

MZ Clonidine HCl Injection will be stored in the pharmacy or ward below 25°C. Protect from Light.

Product is for single use in one patient only.

Discard any residue.

Product description

What it looks like:

MZ Clonidine HCl Injection is a clear, colourless solution. It comes in a glass ampoule.

Ingredients:

Each MZ Clonidine HCl Injection contains 150 micrograms clonidine hydrochloride as the active ingredient in 1 mL of solution. It also contains sodium chloride, hydrochloric acid and water for injections.

Supplier

Australian Sponsor

Medicianz Healthcare Pty Limited
Unit 2, 6-7 Gilda Court
Mulgrave Victoria
Australia 3170

Marketed and distributed in Australia by: Medsurge Healthcare Pty Ltd.

Registration Number

AUST R 233725

This leaflet was prepared in 22 October 2018.

Published by MIMS January 2019

BRAND INFORMATION

Brand name

MZ Clonidine HCl Injection

Active ingredient

Clonidine hydrochloride

Schedule

S4

 

Notes

Distributed by Medsurge Healthcare Pty Ltd

1 Name of Medicine

Clonidine hydrochloride.

2 Qualitative and Quantitative Composition

Clonidine hydrochloride 150 microgram/1 mL.
MZ Clonidine HCl Injection 1 mL ampoules contain 150 microgram of clonidine hydrochloride, 9 mg of sodium chloride, hydrochloric acid (qs) and water for injections (qs).

3 Pharmaceutical Form

Solution for injection.
Clear, colourless solution.

4 Clinical Particulars

4.1 Therapeutic Indications

MZ Clonidine HCl Injection is indicated for acute hypertensive crisis and as an alternative to oral therapy where the oral route of administration is inappropriate.

4.2 Dose and Method of Administration

Subcutaneous or intramuscular injection of MZ Clonidine HCl Injection should only be administered to patients in a lying position. Product is for single use in one patient only. Discard any residue.
One to two ampoules (150-300 microgram) by intramuscular injection undiluted, or given intravenously in 10 mL of normal saline over five minutes. May be repeated at intervals of 3 to 6 hours as necessary. Following intravenous injection, an initial pressor phase of 5-10 mmHg lasting approximately 5 minutes may occur. This effect can be lessened by slow administration. As clonidine is metabolised in the liver and excreted mainly by the kidneys, any hepatic or renal impairment may require a reduction in dosage. Clonidine HCl Injection may be given in combination with guanethidine, alpha methyldopa or other antihypertensives to provide effective control of blood pressure in refractory cases. In this way the dose of each individual drug may be reduced and side effects minimised.
MZ Clonidine HCl Injection contain 0.154 mmol sodium (3.5 mg) per ampoule.

Renal insufficiency.

Dosage must be adjusted:
according to the individual antihypertensive response which can show high variability in patients with renal insufficiency;
according to the degree of renal impairment.
Careful monitoring is required. Since only a minimal amount of clonidine is removed during routine haemodialysis, there is no need to give supplemental clonidine following dialysis.

4.3 Contraindications

MZ Clonidine HCl Injection should not be used in patients with known hypersensitivity to the active ingredient, clonidine hydrochloride, and in patients with severe bradyarrhythmia resulting from either sick sinus syndrome or AV block of second or third degree.
In case of rare hereditary conditions that may be incompatible with an excipient of the product (please see Section 4.4 Special Warnings and Precautions for Use) the use of the product is contraindicated.

4.4 Special Warnings and Precautions for Use

Special care should be exercised in treating patients who have a history of depression or who have advanced cerebrovascular disease. Reduction of blood pressure in the latter circumstances may itself cause mental changes. Concurrent administration of tricyclic antidepressants may require adjustment of MZ Clonidine HCl Injection dosage.
Although a transient rise in blood sugar has been noted occasionally in humans treated with MZ Clonidine HCl Injection, which may be due to a pharmacologic alpha-adrenomimetic effect of the drug, no case of induced diabetes mellitus due to MZ Clonidine HCl Injection has been reported. Patients with clinical diabetes mellitus should be watched for a possible increase in their requirements of anti-diabetic therapy.
MZ Clonidine HCl Injection should be used with caution in patients with mild to moderate bradyarrhythmia such as low sinus rhythm, with disorders of cerebral or peripheral perfusion, polyneuropathy, and constipation.
No therapeutic effect of MZ Clonidine HCl Injection can be expected in the treatment of hypertension caused by phaeochromocytoma.
Since MZ Clonidine HCl Injection, and its metabolites are extensively excreted in the urine, careful adjustment of dosage is required in patients with renal insufficiency (see Section 4.2 Dose and Method of Administration, Renal insufficiency).
As with other anti-hypertensives, treatment with clonidine hydrochloride injection should be monitored particularly carefully in patients with heart failure or severe coronary heart disease.
Termination of oral therapy should be gradual (e.g. over more than 7 days).
Sudden cessation of antihypertensive therapy is known to be associated in some instances with rebound hypertension which in some cases may be severe. This may occur with clonidine hydrochloride injection particularly in patients receiving more than the maximum recommended dose of 900 microgram per day.
Following sudden discontinuation of MZ Clonidine HCl Injection after prolonged treatment with high doses, restlessness, palpitations, rapid rise in blood pressure, nervousness, tremor, headache or nausea have been reported.
An excessive rise in blood pressure following discontinuation of MZ Clonidine HCl Injection therapy can be reversed by intravenous phentolamine (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions).
If long-term treatment with a β-blocker needs to be interrupted, the β-blocker should be gradually phased out first, then clonidine.
Patients who wear contact lenses should be warned that treatment with clonidine hydrochloride injection may cause decreased lacrimation.

Use in the elderly.

No data available.

Paediatric use.

The use and the safety of clonidine in children and adolescents has little supporting evidence in randomised controlled trials and therefore cannot be recommended for use in this population.
In particular, when clonidine is used off-label concomitantly with methylphenidate in children with ADHD, serious adverse reactions, including death, have been observed. Therefore, clonidine in this combination is not recommended.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

If the patient is on antihypertensive therapy, care should be taken as even a small dose of clonidine may further lower blood pressure and necessitate adjustment of the antihypertensive regime.
When clonidine hydrochloride is used as an antihypertensive agent additional clonidine for the prophylaxis of migraine or the alleviation of symptoms in menopausal flushing should not be prescribed. Clonidine hydrochloride may potentiate the effects of alcohol, sedatives, hypnotics or other centrally active substances.
Although retinal, lens or corneal damage have not been detected with clonidine therapy, follow up procedures, such as ophthalmoscopy, are recommended.
Substances which raise blood pressure or induce a sodium and water retaining effect such as nonsteroidal anti-inflammatory drugs can reduce the therapeutic effect of clonidine.
Substances with α2-adrenergic receptor blocking properties, such as phentolamine, may abolish the α2-adrenergic receptor mediated effects of clonidine in a dose-dependent way.
Concomitant administration of drugs with a negative chronotropic or dromotropic effect such as β-blockers or digitalis glycosides can cause or potentiate bradycardic rhythm disturbances.
It cannot be ruled out that concomitant administration of a β-blocker will cause or potentiate peripheral vascular disorders.
The antihypertensive effect of clonidine may be reduced or abolished and orthostatic regulation disturbances may be provoked or aggravated by concomitant administration of tricyclic antidepressants or neuroleptics with α-receptor blocking effects.
Based on observations in patients in a state of delirium alcoholicum, it has been suggested that high intravenous doses of clonidine may increase the arrhythmogenic potential (QT prolongation, ventricular fibrillation) of high intravenous doses of haloperidol.

Anaesthesia.

Abrupt withdrawal of MZ Clonidine HCl Injection is undesirable. Limited evidence suggests that it is unnecessary to withdraw MZ Clonidine HCl Injection before anaesthesia and that maintenance of therapy is preferable to abrupt withdrawal. In the peri-operative period MZ Clonidine HCl Injection can, where necessary, be administered parenterally until oral therapy is resumed.
Where therapy with MZ Clonidine HCl Injection is to be suspended before operation, withdrawal should be gradual (i.e. over more than 7 days) and monitored by regular observation of blood pressure.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Clinical studies on the effect of clonidine on human fertility have not been conducted.
Clonidine had no effect on fertility in male or female rats when administered orally at doses up to 0.15 mg/kg/day (35% higher than the maximum recommended total daily dose of clonidine in humans, based on body surface area).
(Category B3)
Clonidine hydrochloride has not shown teratogenic potential when tested in rats, but in some circumstances the incidence of embryonic and perinatal deaths was increased with doses comparable to those used clinically for antihypertensive therapy.
There are limited data from the use of clonidine in pregnant women, but the experience with clonidine hydrochloride since marketing does not include any positive evidence of adverse effect on the foetus. Since this experience cannot exclude such an effect, clonidine hydrochloride should be used during pregnancy only when the benefit clearly justifies the possible risk to the foetus.
Clonidine passes the placental barrier, and may lower the heart rate of the foetus. There is no adequate experience regarding the long-term effects of prenatal exposure.
Clonidine hydrochloride may also induce transitory elevation of blood glucose and impairment of glucose tolerance. Children born to mothers treated with clonidine hydrochloride during pregnancy should be specifically examined for changes in glucose metabolism.
During pregnancy the oral forms of clonidine are preferred. Intravenous injection of clonidine should be avoided.
Non-clinical studies in rats do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Section 4.6 Fertility, Pregnancy and Lactation, Effects on fertility).
Post partum a transient rise in blood pressure in the newborn cannot be excluded.
 Clonidine is excreted in human milk. As the effect on the new-born is not known, infants born to mothers being treated with clonidine hydrochloride should not be breast fed.

4.7 Effects on Ability to Drive and Use Machines

No studies on the effects on the ability to drive and use machines have been performed.
However, patients should be advised that they may experience undesirable effects such as dizziness, sedation and accommodation disorder during treatment with MZ Clonidine HCl Injection. Therefore, caution should be recommended when driving a car or operating machinery. If patients experience the above mentioned side effects they should avoid potentially hazardous tasks such as driving or operating machinery.

4.8 Adverse Effects (Undesirable Effects)

The following adverse events (regardless of causality) and incidences are based on a review of 22 clinical studies comprising 640 patients treated with clonidine hydrochloride.

Endocrine disorders.

≥ 0.01% and < 0.1%: gynaecomastia.

Psychiatric disorders.

≥ 1% and < 10%: depression, sleep disorder.
≥ 0.1% and < 1%: delusional perception, hallucination, nightmare.
Not known: confusional state, libido decreased.

Nervous system disorders.

≥ 10%: dizziness, sedation.
≥ 1% and < 10%: headache.
≥ 0.1% and < 1%: paraesthesia.

Eye disorder.

≥ 0.01% and < 0.1%: lacrimation decreased.
Not known: accommodation disorder.

Cardiac disorders.

≥ 0.1% and < 1%: sinus bradycardia.
≥ 0.01% and < 0.1%: atrioventricular block.
Not known: bradyarrhythmia.

Vascular disorders.

≥ 10%: orthostatic hypotension.
≥ 0.1% and < 1%: Raynaud's phenomenon.

Respiratory, thoracic and mediastinal disorders.

≥ 0.01% and < 0.1%: nasal dryness.

Gastrointestinal disorders.

≥ 10%: dry mouth.
≥ 1% and < 10%: constipation, nausea, salivary gland pain, vomiting.
≥ 0.01% and < 0.1%: colonic pseudo-obstruction.

Skin and subcutaneous tissue disorders.

≥ 0.1% and < 1%: pruritus, rash, urticaria.
≥ 0.01% and < 0.1%: alopecia.

Reproductive system and breast disorders.

≥ 1% and < 10%: erectile dysfunction.

General disorders and administration site conditions.

≥ 1% and < 10%: fatigue.
≥ 0.1% and < 1%: malaise.

Investigations.

≥ 0.01% and < 0.1%: blood glucose increased.
Most adverse effects are mild and tend to diminish with continued therapy.
Occasional reports of abnormal liver function tests and cases of hepatitis have also been reported.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

Symptoms.

The most important features of clonidine overdosage are likely to be bradycardia, sedation, respiratory depression including apnoea and somnolence including coma. Blood pressure response may be variable and may vary from severe hypotension (due to central sympathetic inhibition and vagal stimulation) to severe hypertension (due to direct alpha agonist activity). Treatment must therefore be appropriate to the clinical features (i.v. atropine followed by a pressor amine if necessary in patients with hypotension or an alpha blocker such as phentolamine for patients with hypertension). Other features which may be seen include weakness, vomiting, diminished or absent reflexes, skin pallor, hypothermia, cardiac arrhythmias and constricted pupils with poor reaction to light.

Management.

General supportive measures with regular checks of pulse, B.P., ECG, blood sugar and body temperature should be undertaken. The blood pressure should be monitored carefully for 48 hours following the overdosage, as a later hypertensive phase may be associated with declining blood levels of clonidine.

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

The hypotensive effect of clonidine hydrochloride is produced mostly by its central effect or reducing sympathetic drive. In this respect clonidine hydrochloride differs from previously used anti-hypertensives.
Clonidine hydrochloride neither depletes major catecholamine stores, nor acts as a ganglion blocking agent. The specific and different mode of action of clonidine hydrochloride leads to benefits such as reduced incidence of postural hypotension and only rarely an effect on libido.
The central action of clonidine hydrochloride is ascribed mainly to an action on the bulbar structures of the central nervous system, particularly the sympathetic cardio-accelerator and constrictor mechanisms. This central action leads to decreased sympathetic outflow. Peripheral effects of clonidine hydrochloride include both vasodilatation and vasoconstriction in various vascular beds, and alpha- and possible beta-adrenomimetic effects. A transient rise in blood sugar occurs following large doses of clonidine hydrochloride. In addition a small transient pressor effect (5-10 mmHg systolic blood pressure) lasting approximately five minutes may occur following intravenous use. These effects reflect the alpha-adrenomimetic action of clonidine hydrochloride. The peripheral effects of clonidine hydrochloride generally require isolated organ type preparations for their demonstration, as in the intact animal or man, the central action predominates.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption and distribution.

The pharmacokinetics of clonidine is dose-proportional in the range of 75-300 microgram. Clonidine, the active ingredient of MZ Clonidine HCl Injection is well absorbed from the gastrointestinal tract and undergoes a minor first pass effect. Peak plasma concentrations are reached within 1-3 hours after oral administration. The duration of action varies from 6-12 hours, the duration of action being longer in the milder hypertensives. The plasma protein binding is 30-40%.

Metabolism and excretion.

The terminal elimination half-life of clonidine has been found to range from 9-26 hours in patients with normal renal function. With impaired renal function it has been reported to increase to 18-48 hours.
The metabolic pathway of clonidine involves cleavage of the imidazolidine ring and the hydroxylation of the phenyl ring. Five metabolites have been identified in man and include para-hydroxy-clonidine and dichlorophenylguanidine.
Two thirds of an administered dose is excreted in the urine (about half of which is unchanged clonidine hydrochloride) and the remainder is excreted in the faeces.
The antihypertensive effect is reached at plasma concentrations between about 0.2 and 2.0 nanogram/mL in patients with normal renal function. The hypotensive effect is attenuated or decreases with plasma concentrations above 2.0 nanogram/mL.
Given intravenously MZ Clonidine HCl Injection is effective within five minutes, has a maximum hypotensive action within 20 to 30 minutes, and the effect lasts for several hours. Following intramuscular administration, MZ Clonidine HCl Injection is effective within 5 to 10 minutes. The maximum hypotensive effect is reached after 75 minutes and the duration of action is approximately 5 hours.
In a study designed to evaluate the pharmacokinetics of clonidine following administration of clonidine hydrochloride controlled release tablets (formulation not registered in Australia) in 30 patients (13 white patients, 6 black patients and 11 Hispanic patients), the pharmacokinetics was found to be similar between subjects from different racial groups.
The pharmacokinetics of clonidine is not influenced by food.

5.3 Preclinical Safety Data

Genotoxicity.

Comprehensive investigations have not been performed to assess the potential genotoxic effects of clonidine. Clonidine showed no activity in the Ames test for mutagenicity or mouse micronucleus test for clastogenicity.

Carcinogenicity.

The carcinogenic potential of clonidine has not been assessed in an adequate range of studies. In rats, dietary administration of clonidine at doses up to 1.2 mg/kg/day (males) or 1.5 mg/kg/day (females) did not cause carcinogenic effects. These doses are 10-14 times the maximum recommended human daily dose of clonidine, based on body surface area.

6 Pharmaceutical Particulars

6.1 List of Excipients

See Section 2 Qualitative and Quantitative Composition.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

5 years.

6.4 Special Precautions for Storage

MZ Clonidine HCl Injection ampoules should be stored below 25°C. Protect from light.

6.5 Nature and Contents of Container

MZ Clonidine HCl Injection solution is available in 1 mL clear glass ampoules and contains 150 microgram of clonidine hydrochloride. Pack size 5 x 1 mL and 10 x 1 mL.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Clonidine hydrochloride is a white or almost white, crystalline powder. It is soluble in ethanol, slightly soluble in chloroform and practically insoluble in ether. One gram is soluble in 13 mL of water (20°C).
Chemical name: 2,6-dichloro-N-2-imidazolidinylidene-benzenamine hydrochloride.
Molecular formula: C9H9N3Cl2.HCl.
Molecular weight: 266.56.
Laboratory designation: ST 155.

Chemical structure.


CAS number.

4205-91-8.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Summary Table of Changes